Literature DB >> 24638138

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

Manuel A Friese1, Benjamin Schattling1, Lars Fugger2.   

Abstract

Multiple sclerosis (MS) is the most frequent chronic inflammatory disease of the CNS, and imposes major burdens on young lives. Great progress has been made in understanding and moderating the acute inflammatory components of MS, but the pathophysiological mechanisms of the concomitant neurodegeneration--which causes irreversible disability--are still not understood. Chronic inflammatory processes that continuously disturb neuroaxonal homeostasis drive neurodegeneration, so the clinical outcome probably depends on the balance of stressor load (inflammation) and any remaining capacity for neuronal self-protection. Hence, suitable drugs that promote the latter state are sorely needed. With the aim of identifying potential novel therapeutic targets in MS, we review research on the pathological mechanisms of neuroaxonal dysfunction and injury, such as altered ion channel activity, and the endogenous neuroprotective pathways that counteract oxidative stress and mitochondrial dysfunction. We focus on mechanisms inherent to neurons and their axons, which are separable from those acting on inflammatory responses and might, therefore, represent bona fide neuroprotective drug targets with the capability to halt MS progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638138     DOI: 10.1038/nrneurol.2014.37

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  165 in total

Review 1.  NMDA receptor pathways as drug targets.

Authors:  John A Kemp; Ruth M McKernan
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

2.  Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  B Kornek; M K Storch; J Bauer; A Djamshidian; R Weissert; E Wallstroem; A Stefferl; F Zimprich; T Olsson; C Linington; M Schmidbauer; H Lassmann
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

3.  Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis.

Authors:  Jagat R Kanwar; Rupinder K Kanwar; Geoffrey W Krissansen
Journal:  Brain       Date:  2004-05-06       Impact factor: 13.501

Review 4.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway.

Authors:  Thomas W Kensler; Nobunao Wakabayashi; Shyam Biswal
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

5.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists.

Authors:  T Smith; A Groom; B Zhu; L Turski
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis.

Authors:  D C Shields; W R Tyor; G E Deibler; E L Hogan; N L Banik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

7.  The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis.

Authors:  Delinda A Johnson; Sara Amirahmadi; Charlotte Ward; Zsuszanna Fabry; Jeffrey A Johnson
Journal:  Toxicol Sci       Date:  2009-11-12       Impact factor: 4.849

8.  Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis.

Authors:  Getaw Worku Hassen; Jason Feliberti; Leo Kesner; Alfred Stracher; Foroozan Mokhtarian
Journal:  Brain Res       Date:  2008-08-12       Impact factor: 3.252

9.  Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.

Authors:  Sandra Vergo; Matthew J Craner; Ruth Etzensperger; Kathrine Attfield; Manuel A Friese; Jia Newcombe; Margaret Esiri; Lars Fugger
Journal:  Brain       Date:  2011-01-13       Impact factor: 13.501

Review 10.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.

Authors:  Giles E Hardingham; Hilmar Bading
Journal:  Nat Rev Neurosci       Date:  2010-09-15       Impact factor: 34.870

View more
  179 in total

1.  Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.

Authors:  Erez Eitan; Emmette R Hutchison; Nigel H Greig; David Tweedie; Hasan Celik; Soumita Ghosh; Kenneth W Fishbein; Richard G Spencer; Carl Y Sasaki; Paritosh Ghosh; Soumen Das; Susheela Chigurapati; James Raymick; Sumit Sarkar; Srinivasulu Chigurupati; Sudipta Seal; Mark P Mattson
Journal:  Exp Neurol       Date:  2015-08-13       Impact factor: 5.330

2.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

3.  Relationship between thiol-disulphide homeostasis and visual evoked potentials in patients with multiple sclerosis.

Authors:  Gönül Vural; Şadiye Gümüşyayla; Orhan Deniz; Salim Neşelioğlu; Özcan Erel
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

Review 4.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

5.  Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis.

Authors:  Pernille M Madsen; Stephanie S Sloley; Alberto A Vitores; Melissa M Carballosa-Gautam; Roberta Brambilla; Ian D Hentall
Journal:  Neuroscience       Date:  2017-01-29       Impact factor: 3.590

6.  Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Authors:  Polyxeni Stamati; Vasileios Siokas; Athina-Maria Aloizou; Emmanouil Karampinis; Stylianos Arseniou; Valerii N Rakitskii; Aristidis Tsatsakis; Demetrios A Spandidos; Illana Gozes; Panayiotis D Mitsias; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

7.  Imaging of radicals following injury or acute stress in peripheral nerves with activatable fluorescent probes.

Authors:  Haiying Zhou; Ying Yan; Xueping Ee; Daniel A Hunter; Walter J Akers; Matthew D Wood; Mikhail Y Berezin
Journal:  Free Radic Biol Med       Date:  2016-09-28       Impact factor: 7.376

Review 8.  The CNS under pathophysiologic attack--examining the role of K₂p channels.

Authors:  Petra Ehling; Manuela Cerina; Thomas Budde; Sven G Meuth; Stefan Bittner
Journal:  Pflugers Arch       Date:  2014-12-09       Impact factor: 3.657

Review 9.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22

10.  Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortex.

Authors:  Martine El-Etr; Marion Rame; Celine Boucher; Abdel M Ghoumari; Narender Kumar; Philippe Liere; Antoine Pianos; Michael Schumacher; Regine Sitruk-Ware
Journal:  Glia       Date:  2014-08-04       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.